Suspected Greater Celandine hepatotoxicity: Liver-specific causality evaluation of published case reports from Europe

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 3, 2012, Pages 270-280

  Teschke, Rolf ^a   Glass, Xaver ^b   Schulze, Johannes ^b   Eickhoff, Axel ^a  

^a Department of Internal Medicine II   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Chelidonium majus; Chelidonium majus hepatotoxicity; Greater Celandine; Greater Celandine hepatotoxicity; herb induced liver injury; herbal hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHELIDONIUM EXTRACT; HERBACEOUS AGENT; ROXITHROMYCIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIARY SPASM; BILIARY TRACT DISEASE; BLOATING; CHOLELITHIASIS; CLINICAL ARTICLE; CONSTIPATION; CURCUMA; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG INDICATION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EUROPE; FATIGUE; FECES COLOR; FEMALE; GALLBLADDER DISEASE; GENTIAN; HEARTBURN; HERB INDUCED LIVER INJURY; HUMAN; HUMAN TISSUE; INSOMNIA; JAUNDICE; LIVER HISTOLOGY; LIVER INJURY; LIVER TOXICITY; LYCOPODIUM; LYCOPODIUM SERRATA; MALE; MYALGIA; NAUSEA; NIGHT SWEAT; PRIORITY JOURNAL; PRURITUS; PUBLICATION; SIDE EFFECT; SKIN PRURITUS; UPPER ABDOMINAL PAIN; URINE COLOR; VOMITING; WEAKNESS;

CHELIDONIUM; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; EUROPE; HUMANS; MEDICAL RECORDS; PHYTOTHERAPY; PLANT EXTRACTS; TIME FACTORS;

EID: 84856701742     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834f993f     Document Type: Article

References (42)

1. Blumenthal M, Lindstrom A, Lynch ME, Rea P. Herb sales continue growth -up 3.3% in 2010. Herbal Gram 2011; 90:64-67.
2. Hung SK, Hillier S, Ernst E. Case reports of adverse effects of herbal medicinal products (HMPs): a quality assessment Phytomedicine 2011; 18:335-343.
3. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11:577-596. (Pubitemid 47302344)
4. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 24:373-382.
5. Teschke R, Bahre R. Severe hepatotoxicity by Indian ayurvedic herbal products: a structured causality assessment Ann Hepatol 2009; 8: 258-266.
6. Pak E, Esrason KT, Wu VH. Hepatotoxicity by herbal remedies: an emerging dilemma. Prog Transplant 2004; 14:91-96.
7. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20:1182-1193.
8. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 11:249-259.
9. European Medicines Agency (EMA). Assessment report on Chelidonium majus L., herba. Draft. 25November 2010. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Public-statement/2011/01/ WC500100940.pdf [Accessed July 15 2011].
10. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal medication (extracts of kava or of common or lesser celandine). Dtsch Med Wochenschr 1998; 123:1410-1414 (in German). (Pubitemid 28545594)
11. Greving I, Meister V, Monnerjahn C, Müller KM, May B. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Saf 1998; 7:S66-S69. (Pubitemid 28343432)
12. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Gastroenterology 1999; 117:1234-1237. (Pubitemid 29512684)
13. Crijns AP, de Smet PA, van den Heuvel M, Schot BW, Haagsma EB. Acute hepatitis after use of herbal preparation with greater celandine (Chelidonium majus). Ned Tijdschr Geneeskd 2002; 146:124-128, (in Dutch). (Pubitemid 34075663)
14. Stickel F, Pöschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003; 38:565-568. (Pubitemid 36609866)
15. Rifai K, Flemming P, Manns MP,Trautwein C. Severe drug hepatitis caused by Chelidonium majus. Internist 2006; 47:749-751 (in German). (Pubitemid 44014295)
16. Hardeman E, van Overbeke L, Ilegems S, Ferrante M. Acute hepatitis induced by greater celandine (Chelidonium majus). Acta Gastroenterol Belg 2003; 71:281-282.
17. Conti E, De Checchi G, Mencarelli R, Pinato S, Rovere P. Lycopodium similiaplex-induced acute hepatitis: a case report. Eur J Gastroenterol Hepatol 2008; 20:469-471. (Pubitemid 351533885)
18. Moro PA, Cassetti F, Giugliano G, Falce MT, Mazzanti G, Menniti-Ippolito F, et al. Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 2009; 124:328-332.
19. Tarantino G, Di Minno MND, Pezullo MG, Pezzullo LS, Milone F, Milone M, Capone D. Drug-induced liver injury due to ''natural products'' used for weight loss: a case report. World J Gastroenterol 2009; 15:2414-2417.
20. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330. (Pubitemid 23333873)
21. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66:758-766.
22. Bf Ar M (Bundesinstitut für Arzneimittel und Medizinprodukte). Federal Institute for Drugs and Medicinal Products, Bonn, Germany Announcement. Preventing dangers by drugs, step II, hearing: drugs containing Greater Celandine for internal use. 6 May 2005. Available at: http://www.bfarm.de/ cae/servlet/contentblob/1014620/publication File/66198/schoellkraut-an hoerung-050505.pdf [Accessed 15 July 2011].
23. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues.Ann Hepatol 2009; 8:184-195.
24. Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61:282-291.
25. Colombo ML, Bosisio E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res 1996; 33:127-134. (Pubitemid 26275877)
26. Mazzanti G, Di Sotto A, Franchitto A, Mammola CL, Mariani P, Mastrangelo S, et al. Chelidonium majus is not hepatotoxic in Wistar rats, in a 4 weeks feeding experiment. J Ethnopharmacol 2009; 126:518-524.
27. Mammola C,Vitalone A, Di Sotto A, Mariani P, Izzo P, Mazzanti G. In vitroand in vivo studies on the hepatic effect of acute administration of Chelidonium majus alone or in association with acetaminophen. Ital J Anat Embryol 2010; 115 (No. 1/2 Supplement):97.
28. Rudolf H, Ullrich A, Ludwig K, Runge D. Hepatotoxic assessment of Chelidonium majus L. and its alkaloids in primary cultures of different species. Available at: http://www.hepatozyten.de/pdf/Schoellkrautpdf [Accessed 15July 2011].
29. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011; 7:875-890.
30. Au JS, Navarro VJ, Rossi S. Review article: drug induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 2011; 34:11-20.
31. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonachini M, et al. for the US Drug-induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51:2117-2126.
32. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al. For the Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48:1175-1183.
33. Garcia-Cortéz M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008; 27:780-789. (Pubitemid 351490076)
34. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, Garć?a-Ruiz E, et al. Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registryover a 10-yearperiod. Gastroenterology 2005; 129:512-521. (Pubitemid 41096639)
35. Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine 2003; 10 (Suppl IV):68-73. (Pubitemid 36597161)
36. Teschke R. Kava hepatotoxicity - a clinical review. Ann Hepatol 2010; 9:251-265.
37. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf 2011; 20:567-582.
38. Agarwal VK, Mc Hutchison JG, Hoofnagle JH. Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8:463-470.
39. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141:1665-1672
40. WHO. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC). Database, 2000. Available at www.who-umc.org/ Dyn Page.aspx?id=22682 [Accessed 15 July, 2011].
41. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245. (Pubitemid 12149145)
42. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharmacol 2011; 59:1-7.